Results 81 to 90 of about 61,613 (221)
PharmaceuticsBackground/Objectives: Irinotecan is used in monotherapy or combined with other drugs for treating different cancer streams. SN-38, the active metabolite of irinotecan, is 70% inactivated by the uridine diphosphate (UDP) glucuronosyltransferase family 1 ...
Xando Díaz-Villamarín +9 more
doaj +1 more source
Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer
International Journal of Cancer, EarlyView.ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue +6 more
wiley +1 more source
Pharmacogenomics in Cancer Treatment: Challenges and Opportunities in African Settings. [PDF]
Cancer MedABSTRACT Background Cancer incidence in Africa is projected to reach 2.1 million new cases annually by 2040. Current treatment guidelines remain largely based on pharmacogenomic data predominantly from European and Asian genetic profiles, potentially compromising safety and efficacy in African patients.
Maphumulo NF, Rebello G, Ramsuran V.
europepmc +2 more sources
International Journal of Gynecology &Obstetrics, EarlyView.Abstract Lynch syndrome and BRCA‐mutation associated malignancies are fortunately rare. Affected patients have an increased risk of cancer diagnosis at a young age, often significantly overlapping with their reproductive years. In helping these patients, oncologists must navigate the following areas of care: cancer prevention, impact of cancer ...
Anna Weimer +20 more
wiley +1 more source
Journal of Surgical Oncology, EarlyView.ABSTRACT Introduction The PRODIGE 24/CCTG PA.6‐ trial has shown an overall survival (OS) up to 55 months in patients treated with (modified) 5‐fluorouracil, leucovorin, irinotecan and oxaliplatin ((m)FOLFIRINOX) chemotherapy after resection of pancreatic ductal adenocarcinoma (PDAC). The applicability of these results to a real‐world patient population
N. C. Biesma +7 more
wiley +1 more source
Optimization of irinotecan chronotherapy with P-glycoprotein inhibition
, 2014 The relevance of P-glycoprotein (P-gp) for irinotecan chronopharmacology was investigated in female B6D2F1 mice. A three-fold 24 h change in the mRNA expression of Abcb1b was demonstrated in ileum mucosa, with a maximum at Zeitgeber Time (ZT) 15 (p < 0 ...
VAN DER HORST, Gijsbertus T. J. +15 more
core +2 more sources
AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma
Medicinal Research Reviews, EarlyView.ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy characterized by late diagnosis, high recurrence rates, and pronounced chemoresistance. While nanoparticle‐based drug delivery systems (NDDS) offer theoretical advantages over conventional therapies, their clinical translation in PDAC has been severely limited.
Seohyun Choo +4 more
wiley +1 more source
UGT1A1 polymorphisms in cancer: impact on irinotecan treatment
, 2017 Masashi Takano1 Toru Sugiyama2 1Department of Clinical Oncology, National Defense Medical College Hospital, Tokorozawa, Saitama, 2Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Iwate, Japan Abstract: Mutations in the UGT1A1 ...
Takano M, Sugiyama T
core
Irinotecan combined with KML001 has an additive inhibitory effect in CT26 isograft models.
, 2013 (A) At 24 h after being injected with irinotecan (once weekly), injected with KML001 (once weekly). (B) At 24 h and 72 h after being injected with irinotecan (once weekly), injected with KML001 (twice weekly).
Ho-Taek Song (289429) +11 more
core +1 more source
Phytotherapy Research, EarlyView.ABSTRACT Asthma affects 260–300 million people worldwide. About 20%–35% of patients use medicinal plants with their asthma medication, often without telling their clinicians. Disclosure rates are low; up to 42% of asthma outpatients use herbal products, with no records in their charts.
Emine Kocyigit +5 more
wiley +1 more source